227 related articles for article (PubMed ID: 2059433)
1. Human graft-versus-host disease.
Parkman R
Immunodefic Rev; 1991; 2(4):253-64. PubMed ID: 2059433
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
3. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K
Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-host disease after marrow transplantation.
Storb R
Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
[TBL] [Abstract][Full Text] [Related]
5. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
[TBL] [Abstract][Full Text] [Related]
6. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
7. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
[TBL] [Abstract][Full Text] [Related]
8. Chronic graft-versus-host disease.
Cutler C; Antin JH
Curr Opin Oncol; 2006 Mar; 18(2):126-31. PubMed ID: 16462180
[TBL] [Abstract][Full Text] [Related]
9. T cell immunity and graft-versus-host disease (GVHD).
Ichiki Y; Bowlus CL; Shimoda S; Ishibashi H; Vierling JM; Gershwin ME
Autoimmun Rev; 2006 Jan; 5(1):1-9. PubMed ID: 16338205
[TBL] [Abstract][Full Text] [Related]
10. GVHD pathophysiology: is acute different from chronic?
Toubai T; Sun Y; Reddy P
Best Pract Res Clin Haematol; 2008 Jun; 21(2):101-17. PubMed ID: 18503979
[TBL] [Abstract][Full Text] [Related]
11. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
[TBL] [Abstract][Full Text] [Related]
12. Effector cells of graft-versus-host disease, host resistance, and the graft-versus-leukemia effect: summary of a workshop on bone marrow transplantation.
Ringdén O; Deeg HJ; Beschorner W; Slavin S
Transplant Proc; 1987 Feb; 19(1 Pt 3):2758-61. PubMed ID: 3547953
[No Abstract] [Full Text] [Related]
13. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate.
Tollemar J; Ringdén O; Heimdahl A; Lönnqvist B; Sundberg B
Transplant Proc; 1988 Jun; 20(3 Suppl 3):470-9. PubMed ID: 3291283
[No Abstract] [Full Text] [Related]
14. [Graft versus host reaction and hybrid resistance in experimental models and clinical practice].
Clerici M; Villa ML; Clerici E
Boll Ist Sieroter Milan; 1988; 67(3):177-96. PubMed ID: 3072013
[TBL] [Abstract][Full Text] [Related]
15. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
[TBL] [Abstract][Full Text] [Related]
16. Relapse of host leukemic lymphoblasts following engraftment by an HLA-mismatched marrow transplant: mechanisms of escape from the "graft versus leukemia" effect.
Sondel PM; Hank JA; Molenda J; Blank J; Borcherding W; Longo W; Trigg ME; Hong R; Bozdech MJ
Exp Hematol; 1985 Sep; 13(8):782-90. PubMed ID: 2931298
[TBL] [Abstract][Full Text] [Related]
17. B-cell involvement in chronic graft-versus-host disease.
Kapur R; Ebeling S; Hagenbeek A
Haematologica; 2008 Nov; 93(11):1702-11. PubMed ID: 18728020
[TBL] [Abstract][Full Text] [Related]
18. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-leukemia following bone marrow transplantation.
Butturini A; Bortin MM; Gale RP
Bone Marrow Transplant; 1987 Oct; 2(3):233-42. PubMed ID: 3332173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
